Printer Friendly
The Free Library
14,505,210 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Guidant Launches Innovative Cobalt Chromium Biliary Stent; RX HERCULINK ELITE Biliary Stent System Provides Superb Deliverability With Increased Radial Strength, Visibility and Stent Flexibility.


INDIANAPOLIS & SANTA CLARA, Calif. -- Guidant Corporation (NYSE NYSE

See: New York Stock Exchange
:GDT GDT Global Descriptor Table
GDT Geographic Data Technology Inc.
GDT Gas Discharge Tube (energy, electrotechinical and electronics)
GDT Getting Things Done
GDT Geometric Dimensioning & Tolerancing
GDT Ground Data Terminal
) today announced that the company has launched the RX HERCULINK(R) ELITE(TM) Biliary Stent biliary stent Biliary endoprosthesis Surgery A tube inserted into a stenosed or obstructed narrowed or blocked bile duct to improve bile flow  System in the United States, following U.S. Food and Drug Administration (FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
) 510(k) clearance. The company also received Conformite Europeene (CE) Mark approval, and has begun marketing the stent system in the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the

European Community
.

The RX HERCULINK ELITE Biliary Stent System is the industry's first .014 rapid-exchange biliary stent system using cobalt chromium, a material that is stronger and more radiopaque ra·di·o·paque
adj.
Relatively impenetrable by x-rays or other forms of radiation.


radiopaque (rā´dēōpāk´),
adj
 than stainless steel stainless steel: see steel.
stainless steel

Any of a family of alloy steels usually containing 10–30% chromium. The presence of chromium, together with low carbon content, gives remarkable resistance to corrosion and heat.
. This new stent system improves on Guidant's previous generation of .014 biliary stents by increasing flexibility and radial strength, and making the stent more visible and deliverable.

"With RX HERCULINK's legacy of proven deliverability and the advantages of cobalt chromium, the RX HERCULINK ELITE Biliary Stent System is the next generation of biliary stenting technology," said Ron Lattanze, president, Endovascular Solutions, Guidant Corporation. "Guidant remains focused on providing innovative products to physicians and their patients."

Guidant introduced the RX HERCULINK Biliary Stent System, the first .014 biliary system, in 1999, and the enhanced RX HERCULINK(R) PLUS Biliary Stent System in 2001. In the United States, the RX HERCULINK PLUS Biliary Stent System and RX HERCULINK ELITE Biliary Stent System are indicated for the treatment of malignant biliary obstructions, blockages found in the ducts that carry fluids from the liver to the gallbladder or from the gallbladder to the small intestine. These obstructions affect more than 30,000 patients in the United States each year.

Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. The company, driven by a strong entrepreneurial culture of 12,000 employees, develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions. For more information visit www.guidant.com.

NOTE TO MEDIA: For more information about Guidant, including its products and services, please visit the company's newsroom at www.guidant.com/newsroom.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 9, 2006
Words:340
Previous Article:Wherify and SEAC Bring Enhanced GPS-Based Personal Location Services to Argentina; SEAC Commits to Initial Purchase of 15,000 Wherifones.
Next Article:Fitch Rates The National Collegiate Student Loan Trust 2006-1.
Topics:



Related Articles
Guidant Announces Positive Preliminary Results of Large Real-World Carotid Artery Stenting Study; Study Suggests Therapy Can Be Performed Safely by...
Guidant Completes Enrollment in International Drug Eluting Stent Clinical Trial; Data from Study Will Support Launch of XIENCE V Coronary Stent...
Guidant Reports Excellent 12-Month Results from SPIRIT FIRST Everolimus Eluting Coronary Stent Clinical Trial; Results Demonstrate Sustained Benefit...
Guidant Enrolls First Patient in Japan Arm of Drug Eluting Stent Trial; SPIRIT III U.S. Randomized Enrollment Passes Halfway Mark.
Guidant Receives Recommendation for Approval from European Competent Authority for Drug Eluting Stent; Company Has Successfully Completed Conformity...
Guidant Announces Enrollment of First Patient in Clinical Trial of the World's First Fully Bioabsorbable Drug Eluting Coronary Stent; Innovative...
Circulation Article Reports That Medtronic's Endeavor(R) Drug-Eluting Stent Provides Further Evidence of Effective, Safe and Sustained Clinical...
Medtronic Micro-Driver Coronary Stent Approved in Japan.
Medtronic Announces Regulatory Approval for the Endeavor Drug-Eluting Coronary Stent System in Australia.
Medtronic Achieves Key Milestones in Rapidly Growing Peripheral Vascular Business.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles